Stamp was FD at both Shire and Regus when they completed their initial public offers on the London Stock Exchange, as well as overseeing a number of major acquisitions and financings.
As well as at Shire, he has held senior positions in a number of healthcare companies, including as chief operating officer of Xanodyne Pharmaceuticals and most recently with AIM-quoted Ergomed PLC.
After being promoted from CFO to CEO, Stamp stood down from Ergomed earlier this year.
Nick Robbins-Cherry has stepped down as CFO after five years at Midatech but will remain employed until the end of October as part of the handover process.
Chief executive Craig Cook said Stamp’s career “makes him very well suited to support the execution of our strategy at this important and exciting time for the company”.
He added: “I very much look forward to working closely with him to drive forward the development of our business as we focus on getting our clinical research assets through clinical development, approval, and onto successful commercialisation.”